Takeda Pharmaceutical Company

Finch Therapeutics & Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery® Platform

Retrieved on: 
Wednesday, November 13, 2019
Infectious diseases, Biotechnology, Pharmaceutical, Health, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Colitis, Takeda Pharmaceutical Company, Ulcerative colitis, Inflammatory bowel disease, Takeda

Finch Therapeutics Group, Inc. (Finch) and Takeda Pharmaceutical Company Limited (Takeda; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finchs Human-First Discovery platform.

Key Points: 
  • Finch Therapeutics Group, Inc. (Finch) and Takeda Pharmaceutical Company Limited (Takeda; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finchs Human-First Discovery platform.
  • Under the terms of the expanded agreement, Finch and Takeda will utilize Finchs platform to target Crohns disease, a form of inflammatory bowel disease.
  • In collaboration with Takeda, Finchs first RSM product, FIN-524, is advancing through pre-clinical development for the treatment of ulcerative colitis.
  • We are pleased to expand our collaboration with Takeda, said Mark Smith, PhD, CEO of Finch.

Poxel Announces Positive Update Following FDA Meeting for PXL065 for Treatment of NASH

Retrieved on: 
Friday, November 8, 2019
FDA, Health, Diabetes, Clinical trials, Pharmaceutical, Biotechnology, CYP17A1 inhibitors, Pyridines, Thiazolidinediones, Pioglitazone, RTT, Takeda Pharmaceutical Company, Thiazolidinedione, Chemical substances, Chemistry

PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, is a mitochondrial pyruvate carrier (MPC) inhibitor being developed for the treatment of NASH.

Key Points: 
  • PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, is a mitochondrial pyruvate carrier (MPC) inhibitor being developed for the treatment of NASH.
  • We plan to initiate a Phase 2 trial for PXL065 for the treatment of NASH during the second quarter of 2020 in biopsy-proven NASH patients.
  • Based upon preclinical and Phase 1 results to date, Poxel believes that PXL065 may have a better therapeutic profile than pioglitazone for NASH.
  • PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH.

Poxel to Present Results From Phase 1a Study of PXL065 at the Liver Meeting® 2019

Retrieved on: 
Thursday, November 7, 2019
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Pioglitazone, Pyridines, RTT, Takeda Pharmaceutical Company, Thiazolidinediones, Thiazolidinedione, MPC, Chemical substances

ePoster stations will be available throughout the meeting to provide continuous viewing access during and after the meeting in LiverLearning.

Key Points: 
  • ePoster stations will be available throughout the meeting to provide continuous viewing access during and after the meeting in LiverLearning.
  • In in vitro studies, PXL065 has been shown to target mitochondrial pyruvate carrier (MPC) as an inhibitor.
  • Based upon preclinical and Phase 1 results to date, Poxel believes that PXL065 may have a better therapeutic profile than pioglitazone for NASH.
  • PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH.

Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

Retrieved on: 
Thursday, November 7, 2019
Oncology, Health, Stem cells, Clinical trials, Pharmaceutical, Biotechnology, Orphan drugs, Takeda Pharmaceutical Company, Multiple myeloma, RTT, Boronic acids, Ixazomib, Clinical medicine, Medicine, Health, Plasma cell dyscrasias, Lenalidomide, the TOURMALINE-MM4 Trial, Multiple Myeloma, NINLAROTM

The trial evaluated the effect of single-agent oral NINLARO (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation.

Key Points: 
  • The trial evaluated the effect of single-agent oral NINLARO (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation.
  • We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients.
  • The typical multiple myeloma disease course includes periods of symptomatic myeloma followed by periods of remission.
  • Nearly 230,000 people around the world live with multiple myeloma, with approximately 114,000 new cases diagnosed globally each year.

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting

Retrieved on: 
Thursday, November 7, 2019
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Cancer treatments, Medical specialties, Medicine, Monoclonal antibodies, Takeda Pharmaceutical Company, Seattle Genetics, Antibody-drug conjugates, Brentuximab vedotin, CD30, Immunology, Antibody-drug conjugate, Monomethyl auristatin E

ADCETRIS is being evaluated globally as the foundation of care for CD30-expressing lymphomas in more than 70 corporate- and investigator-sponsored clinical trials.

Key Points: 
  • ADCETRIS is being evaluated globally as the foundation of care for CD30-expressing lymphomas in more than 70 corporate- and investigator-sponsored clinical trials.
  • At this years ASH meeting, ADCETRIS will be featured in 15 data presentations, including updated analyses from ECHELON-1 and ECHELON-2 phase 3 frontline trials, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.
  • We continue to invest in our ADCETRIS clinical development program with the goal of improving outcomes for patients.
  • ADCETRIS (brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.

Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Organ systems, Medicine, Clinical medicine, Pain, Brentuximab vedotin, Takeda Pharmaceutical Company, Peripheral neuropathy, Neurological disorders, Hypoesthesia, Neuropathic pain, Dysesthesia, Paresthesia, ICLUSIG® (ponatinib) tablets, NINLARO™

Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.

Key Points: 
  • Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.
  • Available data indicate that MMAE clearance might be affected by severe renal impairment, hepatic impairment, and by low serum albumin concentrations.
  • Patients who are receiving a strong CYP3A4 and P-gp inhibitor, concomitantly with ADCETRIS may have an increased risk of neutropenia.
  • In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.

Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany

Retrieved on: 
Tuesday, November 5, 2019
Infectious diseases, Biotechnology, Pharmaceutical, Health, Health sciences, Health, Vaccines, Pharmaceutical sciences, Dengue fever, Dengue vaccine, Virology, Takeda Pharmaceutical Company, Vaccine, Pharmaceutical industry, Takeda

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003.
  • The Singen vaccine plant will be utilized for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line.
  • Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant.
  • View the full release here: https://www.businesswire.com/news/home/20191105005718/en/
    Takeda senior leaders are joined by honored guests and employees at the grand opening of Takedas dengue vaccine manufacturing plant in Singen, Germany.

Atacand - Drug Insight Study 2019 with Worldwide Sales Forecasted to 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 4, 2019
Health, Pharmaceutical, Chemical compounds, Organic compounds, Benzimidazoles, Candesartan, Ethers, Takeda Pharmaceutical Company, Tetrazoles, SWOT analysis, SWOT

The "Atacand- Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atacand- Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Atacand Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report covers the Global Market Assessment of the Atacand covering the historical global sales and also provides the Atacand sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Atacand and emerging therapies in this space.

Arvelle Therapeutics Strengthens Management Team with Key New Hires

Retrieved on: 
Thursday, October 31, 2019
Companies, Health, Articles, Takeda Pharmaceutical Company, Shire, Bayer, Pharmaceutical industry in China, Petra, Takeda, Pharmaceutical industry

Petra joins Arvelle from Takeda Pharmaceuticals where she was SVP, Global Head of Rare Hematology Franchise, Patient Value & Product Strategy.

Key Points: 
  • Petra joins Arvelle from Takeda Pharmaceuticals where she was SVP, Global Head of Rare Hematology Franchise, Patient Value & Product Strategy.
  • Prior to that she held the position of GVP, Global Head of Internal Medicine Franchise, Global Strategic Marketing at Shire.
  • Prior to her global strategic roles at Takeda and Shire, Petra held several senior commercial leadership positions at Bayer and Lilly.
  • Mark Altmeyer, President and CEO of Arvelle Therapeutics, said: I am delighted to welcome Petra and Enrico to Arvelle at this important time in the Companys development.

Multiple Myeloma Experts, Patients, Advocates and Caregivers Team Up to Hike Through Patagonia

Retrieved on: 
Tuesday, October 22, 2019
Research, Women, Hospitals, MEN, Other Health, Pharmaceutical, Consumer, Health, Science, Oncology, Drugs, Medicine, Clinical medicine, RTT, Orphan drugs, Takeda Pharmaceutical Company, Norwalk, Connecticut, Immunosuppressants, Lenalidomide, Multiple myeloma, Bortezomib, Multiple Myeloma Research Foundation, Moving Mountains for Multiple Myeloma®, Multiple Myeloma, the Multiple Myeloma Research Foundation, CURE Media Group

The upcoming climb includes survivors, caregivers, family members, myeloma doctors and team members from the organizing partners.

Key Points: 
  • The upcoming climb includes survivors, caregivers, family members, myeloma doctors and team members from the organizing partners.
  • All the funds raised go directly to the MMRF to accelerate new treatment options for patients with multiple myeloma.
  • She began her treatment with the multiple myeloma standard induction therapy of Revlimid (lenalidomide), bortezomib (Velcade) and dexamethasone for four months.
  • Moving Mountains for Multiple Myeloma (MM4MM) is a collaboration between CURE Media Group and the Multiple Myeloma Research Foundation (MMRF) to raise awareness and funds for myeloma research.